Press Room

CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease Type 2S (CMT2S) is a severe axonal type of CMT caused by certain autosomal recessive mutations of the IGHMBP2 gene. CMTA-STAR Alliance Partner Vanda Pharmaceuticals ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT). Building on previous successes, CMTA announced earlier this year a strategic $450,000 investment in ...

THE CHARCOT-MARIE-TOOTH ASSOCIATION SUPPORTS THE ACCELERATING KIDS’ ACCESS TO CARE ACT (H.R.4758 / S.2372) The Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372) is a bipartisan bill that aims to simplify the Medicaid enrollment process, ...

Growing up with a disability presents layers of challenges at school, in social settings, and within our children and teens’ inner lives. Education and disability expert Sarah Kesty will show you and your child or ...

Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Milan, Italy, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR), have made encouraging progress in developing a potential treatment for ...